Shield Christopher G, Swift Benjamin M C, McHugh Timothy D, Dedrick Rebekah M, Hatfull Graham F, Satta Giovanni
Department of Pathobiology and Population Sciences, Royal Veterinary College, Hatfield AL9 7TA, UK.
Centre for Clinical Microbiology, University College London, London NW3 2PF, UK.
Microorganisms. 2021 Nov 16;9(11):2366. doi: 10.3390/microorganisms9112366.
Mycobacterium tuberculosis and other non-tuberculous mycobacteria are responsible for a variety of different infections affecting millions of patients worldwide. Their diagnosis is often problematic and delayed until late in the course of disease, requiring a high index of suspicion and the combined efforts of clinical and laboratory colleagues. Molecular methods, such as PCR platforms, are available, but expensive, and with limited sensitivity in the case of paucibacillary disease. Treatment of mycobacterial infections is also challenging, typically requiring months of multiple and combined antibiotics, with associated side effects and toxicities. The presence of innate and acquired drug resistance further complicates the picture, with dramatic cases without effective treatment options. Bacteriophages (viruses that infect bacteria) have been used for decades in Eastern Europe for the treatment of common bacterial infections, but there is limited clinical experience of their use in mycobacterial infections. More recently, bacteriophages' clinical utility has been re-visited and their use has been successfully demonstrated both as diagnostic and treatment options. This review will focus specifically on how mycobacteriophages have been used recently in the diagnosis and treatment of different mycobacterial infections, as potential emerging technologies, and as an alternative treatment option.
结核分枝杆菌和其他非结核分枝杆菌导致了全球数百万患者受影响的各种不同感染。它们的诊断常常存在问题且会延迟到疾病后期,这需要高度的怀疑指数以及临床和实验室同事的共同努力。分子方法,如聚合酶链反应(PCR)平台,虽已可用,但价格昂贵,且在少菌型疾病情况下敏感性有限。分枝杆菌感染的治疗也具有挑战性,通常需要数月使用多种联合抗生素,伴有相关的副作用和毒性。固有和获得性耐药性的存在使情况更加复杂,出现了一些没有有效治疗选择的严重病例。噬菌体(感染细菌的病毒)在东欧已被用于治疗常见细菌感染数十年,但它们在分枝杆菌感染中的临床应用经验有限。最近,噬菌体的临床效用得到了重新审视,并且其作为诊断和治疗选择已成功得到证明。本综述将特别关注分枝杆菌噬菌体最近如何被用于不同分枝杆菌感染的诊断和治疗,作为潜在的新兴技术以及作为一种替代治疗选择。